APA (7th ed.) Citation

Li, J. Y., Perry, S. R., Muniz-Medina, V., Wang, X., Wetzel, L. K., Rebelatto, M. C., . . . Coats, S. R. (2019). A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. Cancer cell, 35(6), 948-949. https://doi.org/10.1016/j.ccell.2019.05.010

Chicago Style (17th ed.) Citation

Li, John Y., et al. "A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy." Cancer Cell 35, no. 6 (2019): 948-949. https://doi.org/10.1016/j.ccell.2019.05.010.

MLA (9th ed.) Citation

Li, John Y., et al. "A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy." Cancer Cell, vol. 35, no. 6, 2019, pp. 948-949, https://doi.org/10.1016/j.ccell.2019.05.010.